Literature DB >> 590313

Effect of lidocaine on the absorption, disposition and tolerance of intramuscularly administered cefoxitin.

P F Sonneville, K S Albert, H Skeggs, H Gentner, K C Kwan, C M Martin.   

Abstract

The use of lidocaine HCL solution at concentrations of 0.5 and 1.0% to reconstitute sodium cefoxitin relieves the pain associated with intramuscular injections of the antibiotic. Cefoxitin absorption by the intramuscular route is initially rapid and is virtually complete. Peak serum concentrations, corresponding to about one-half those of a comparable intravenous infusion, are achieved in 30 min. Continuing absorption tends to maintain higher serum concentrations for longer times. Renal clearance and serum half-life of cefoxitin do not appear to be affected by lidocaine at its effective anaesthetic concentrations.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 590313     DOI: 10.1007/bf00607426

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

1.  CEPHALOTHIN SERUM LEVELS IN THE AZOTEMIC PATIENT.

Authors:  S A KABINS; S COHEN
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1964

2.  Comparative clinical pharmacology of intravenous cefoxitin and cephalothin.

Authors:  P F Sonneville; R R Kartodirdjo; H Skeggs; A E Till; C M Martin
Journal:  Eur J Clin Pharmacol       Date:  1976-03-22       Impact factor: 2.953

3.  An integrated approach to the pharmacokinetic analysis of drug absorption.

Authors:  A E Till; L Z Benet; K C Kwan
Journal:  J Pharmacokinet Biopharm       Date:  1974-12

4.  An in vivo comparison of cefoxitin, a semi-synthetic cephamycin, with cephalothin.

Authors:  J M Hamilton-Miller; D W Kerry; W Brumfitt
Journal:  J Antibiot (Tokyo)       Date:  1974-01       Impact factor: 2.649

5.  Susceptibility of clinical isolates of bacteria to cefoxitin and cephalothin.

Authors:  R C Moellering; M Dray; L J Kunz
Journal:  Antimicrob Agents Chemother       Date:  1974-09       Impact factor: 5.191

6.  Cefoxitin and cephalothin: antimicrobial activity, human pharmacokinetics, and toxicology.

Authors:  W Brumfitt; J Kosmidis; J M Hamilton-Miller; J N Gilchrist
Journal:  Antimicrob Agents Chemother       Date:  1974-09       Impact factor: 5.191

7.  Cephamycins, a new family of beta-lactam antibiotics. IV. In vivo studies.

Authors:  A K Miller; E Celozzi; Y Kong; B A Pelak; H Kropp; E O Stapley; D Hendlin
Journal:  Antimicrob Agents Chemother       Date:  1972-10       Impact factor: 5.191

8.  A study of the local reaction to intramuscular disodium carbenicillin (Geopen).

Authors:  M M Cahn; E J Levy
Journal:  Curr Ther Res Clin Exp       Date:  1972-09

9.  Cefoxitin, a semisynthetic cephamycin antibiotic: susceptibility studies.

Authors:  H Wallick; D Hendlin
Journal:  Antimicrob Agents Chemother       Date:  1974-01       Impact factor: 5.191

10.  Cefoxitin, a semisynthetic cephamycin antibiotic: resistance to beta-lactamase inactivation.

Authors:  H R Onishi; D R Daoust; S B Zimmerman; D Hendlin; E O Stapley
Journal:  Antimicrob Agents Chemother       Date:  1974-01       Impact factor: 5.191

View more
  4 in total

1.  Investigation of bioequivalence and tolerability of intramuscular ceftriaxone injections by using 1% lidocaine, buffered lidocaine, and sterile water diluents.

Authors:  C J Hayward; A N Nafziger; S J Kohlhepp; J S Bertino
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

2.  Pharmacokinetics and tolerance of ceftriaxone in humans after single-dose intramuscular administration in water and lidocaine diluents.

Authors:  I H Patel; R E Weinfeld; J Konikoff; M Parsonnet
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

Review 3.  Beta-lactams in sexually transmitted diseases: rationale for selection and dosing regimens.

Authors:  D Kunimoto; R Brunham; A Ronald
Journal:  Eur J Clin Microbiol       Date:  1984-12       Impact factor: 3.267

Review 4.  Cefoxitin: a review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-01       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.